Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,060 GBX | +2.32% | +2.71% | -37.02% |
08:14am | UK competition regulator to launch probe into vets market | RE |
May. 21 | CVS sells Dutch and Irish loss-making businesses | AN |
Sales 2024 * | 671M 853M | Sales 2025 * | 719M 915M | Capitalization | 743M 945M |
---|---|---|---|---|---|
Net income 2024 * | 45M 57.25M | Net income 2025 * | 48M 61.06M | EV / Sales 2024 * | 1.43 x |
Net Debt 2024 * | 219M 279M | Net Debt 2025 * | 174M 222M | EV / Sales 2025 * | 1.28 x |
P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
15.1
x | Employees | 9,100 |
Yield 2024 * |
0.76% | Yield 2025 * |
0.82% | Free-Float | 98.47% |
Latest transcript on CVS Group plc
1 day | +3.23% | ||
1 week | +3.63% | ||
Current month | +9.24% | ||
1 month | +12.58% | ||
3 months | -36.15% | ||
6 months | -29.87% | ||
Current year | -36.45% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Fairman
CEO | Chief Executive Officer | 57 | 18-07-31 |
Robin Alfonso
DFI | Director of Finance/CFO | 45 | 19-11-05 |
Richard Killen
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Kemp
BRD | Director/Board Member | 62 | 18-01-01 |
David Wilton
CHM | Chairman | 61 | 21-09-23 |
Richard Fairman
CEO | Chief Executive Officer | 57 | 18-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.84% | 1 M€ | -.--% | ||
0.04% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 1,060 | +2.32% | 399 685 |
24-05-22 | 1,036 | -0.96% | 242,694 |
24-05-21 | 1,046 | -1.32% | 168,509 |
24-05-20 | 1,060 | +5.16% | 1,351,451 |
24-05-17 | 1,008 | -2.33% | 139,236 |
Delayed Quote London S.E., May 23, 2024 at 05:01 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.45% | 946M | |
-9.14% | 178M |
- Stock Market
- Equities
- CVSG Stock